MYELOPROLIFERATIVE NEOPLASMS

This early-stage study is testing the safety and finding the right dose of two drugs, ivosidenib and ruxolitinib, when used together. It is for adults with advanced forms of certain blood cancers that have a specific genetic change (IDH1 mutation). The main goal is to see if the …

This is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 230 people with myeloproliferative neoplasms, a group of blood cancers. The main goal is to see how w…

This is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 225 people with certain blood cancers called myeloproliferative neoplasms. The main goal is to see ho…

This is the first study in people to test a new drug called INCA036978 for myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to find a safe dose and understand the drug's side effects in up to 218 participants with myelofibrosis, polycythemia vera, or …

This is the first study in people to test a new drug called INCB160058 for myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The main goal is to find a safe dose and see how the body processes the drug in 186 adults whose current treatments have stopped working.…

This is the first study in people to test a new drug called INCA035784 for rare blood cancers called myeloproliferative neoplasms. The main goal is to find a safe dose and see what side effects it causes in 120 adults who have not responded well to other treatments. Researchers w…

This is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…